Free Trial
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics logo
$1.74 +0.06 (+3.33%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Gain Therapeutics Stock (NASDAQ:GANX)

Key Stats

Today's Range
$1.66
$1.78
50-Day Range
$1.57
$2.18
52-Week Range
$0.89
$3.19
Volume
91,206 shs
Average Volume
295,795 shs
Market Capitalization
$51.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20
Consensus Rating
Buy

Company Overview

Gain Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

GANX MarketRank™: 

Gain Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 443rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gain Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Gain Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gain Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gain Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gain Therapeutics has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gain Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.82% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently decreased by 20.39%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Gain Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gain Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.82% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently decreased by 20.39%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Gain Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Gain Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.18% of the stock of Gain Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 11.97% of the stock of Gain Therapeutics is held by institutions.

  • Read more about Gain Therapeutics' insider trading history.
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GANX Stock News Headlines

Gain Therapeutics Inc News (GANX) - Investing.com
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Gain Therapeutics (GANX) Gets a Buy from Scotiabank
See More Headlines

GANX Stock Analysis - Frequently Asked Questions

Gain Therapeutics' stock was trading at $2.16 at the beginning of the year. Since then, GANX stock has decreased by 19.6% and is now trading at $1.7360.

Gain Therapeutics, Inc. (NASDAQ:GANX) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16).

Gain Therapeutics (GANX) raised $40 million in an initial public offering (IPO) on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
5/14/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GANX
CIK
1819411
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$6.00
Potential Upside/Downside
+372.4%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.41 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50 thousand
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
6.20

Miscellaneous

Free Float
27,796,000
Market Cap
$51.99 million
Optionable
Optionable
Beta
0.12
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:GANX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners